BZP (Benzylpiperazine) Powder

BZP (Benzylpiperazine) Powder

Product Name: BZP (Benzylpiperazine) Powder Synonyms: 1-Benzylpiperazine; N-benzylpiperazine; A2; Nemesis; Legal X

General Description: BZP is formally described as 1-benzylpiperazine. It is a synthetic, psychoactive molecule belonging to the piperazine class. Originally synthesized in the 1940s and evaluated as a potential anthelmintic (anti-parasitic) and antidepressant, BZP was never successfully commercialized for clinical medical use. However, in the late 1990s and early 2000s, it emerged globally as a recreational designer drug. It was famously marketed in “party pills” or “herbal highs” (particularly in New Zealand and Europe) as a legal alternative to amphetamines and MDMA (Ecstasy), often co-formulated with TFMPP (Trifluoromethylphenylpiperazine) to mimic the entactogenic profile of MDMA.

In analytical, clinical, and forensic toxicology, BZP is utilized as a fundamental reference standard. It is essential for the calibration of analytical instrumentation (such as LC-MS/MS, GC-MS, and HPLC) and the development of screening methodologies to identify and quantify the substance in seized materials, adulterated illicit street drugs, or biological matrices (e.g., whole blood, plasma, urine).

Technical Information (Dihydrochloride Salt): BZP (Benzylpiperazine) Powder 

• CAS Number: 5321-63-1 (Dihydrochloride) / 2759-28-6 (Freebase)
• Molecular Formula: C₁₁H₁₆N₂ • 2HCl
• Formula Weight: 249.18 g/mol (Dihydrochloride) / 176.26 g/mol (Freebase)
• SMILES: C1CNCCN1CC2=CC=CC=C2.Cl.Cl
• InChI Key: WQPRIGQVTJZZDT-UHFFFAOYSA-N (Freebase)
• Formulation: While the freebase of BZP is a pale yellowish liquid at room temperature, it is typically supplied for analytical and illicit purposes as a neat white-to-off-white crystalline powder formulated as a hydrochloride or dihydrochloride salt to ensure stability and solubility. It is also available as a certified reference material solution (e.g., 1 mg/mL in methanol).

Biological Action: BZP acts primarily as a central nervous system stimulant with a pharmacological profile heavily analogous to, though generally less potent than, d-amphetamine. It functions as a monoamine releasing agent and reuptake inhibitor, predominantly targeting the dopamine transporter (DAT) and the norepinephrine transporter (NET). This induces a rapid accumulation of dopamine and norepinephrine in the synaptic cleft. It exhibits a much weaker affinity for the serotonin transporter (SERT). The clinical presentation of acute BZP intoxication includes pronounced wakefulness, euphoria, tachycardia, hypertension, hyperthermia, and dilated pupils. At supratherapeutic doses or in susceptible individuals, it carries a well-documented risk of inducing severe seizures, dehydration, and acute renal or cardiovascular stress.

BZP (Benzylpiperazine) Powder Regulatory and Safety Information:

• Intended Use: This product is intended strictly for use as an analytical reference standard for forensic, toxicological, and academic research purposes.
• Warning: This product is a potent psychostimulant and carries a significant risk of central nervous system overstimulation, severe seizures, cardiovascular collapse, and physiological dependence. It is not for human or veterinary use.